Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periodsJill Corre, Thierry Façon, Xavier Leleu et al.|Leukemia|2021Cited by 41
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Aurore Perrot et al.|Blood|2025Cited by 15